University of Melbourne and Royal Children’s Hospital pediatric oncologist Professor Michael Sullivan was international vice chair of the study, results of which are published in the New England Journal of Medicine.
Sullivan said the trial focused on cisplatin, a potent chemotherapy used to treat cancer in children.
“Cisplatin is a strong, highly effective cancer chemotherapy drug for the treatment of some types of childhood cancer,” Sullivan said. “But in very young children, cisplatin can cause severe and permanent hearing loss that can affect the development of speech and language, and need hearing aids.”
Sullivan said the chemotherapy drug gets into a child’s inner ears and damages tiny hair cells which enable hearing.
The international clinical trial led by Professor Peppy Brock from the Great Ormond Street Children’s Hospital London, involved 116 children at 52 cancer centers in 12 countries including the UK, Europe, the USA, Australia, and New Zealand. It tested whether a drug called sodium thiosulfate (STS) could prevent or reduce the severity of hearing loss in children with primary liver cancer, also known as hepatoblastoma, who were treated with cisplatin.
The study showed that STS administered six hours after cisplatin could reduce the severity of hearing loss without affecting the chance of cure for the cancer.
Of participants who did not receive STS, 66% suffered hearing loss, compared with 33% of those who received STS.
Sullivan said STS, which is a chemical antioxidant used to treat accidental cyanide poisoning, protects the hair cells in the inner ear.
“The overall cure rate for hepatoblastoma in this trial was excellent, with 96% of children disease-free at 3 years, and hearing loss was halved,” he said. “This trial shows we can achieve very high cure rates for some types of childhood cancer while reducing the long-term side effects of chemotherapy. STS is now available, and we have begun using it at the Royal Children’s Hospital in Melbourne.”
Original Paper: Brock PR, Maibach R, Childs M, et al. Sodium thiosulfate for protection from cisplatin-induced hearing loss. New England Journal of Medicine. 2018;378:2376-2385.
Source: University of Melbourne, New England Journal of Medicine